Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients
Sulayman Benmerzoug, Mathieu F. Chevalier, Laura Villier, Sylvain Nguyen, Valérie Cesson, Anna K. Schneider, Florence Dartiguenave, Sonia-Christina Rodrigues-Dias, Ilaria Lucca, Patrice Jichlinski, Beat Roth, Denise Nardelli‐Haefliger, Laurent Derré
Abstract
analysis of Siglec-6 and Siglec-7 expression levels on tumor-infiltrating NK cells (TINKs) from BCa patients showed that only Siglec-7 is expressed by TINKs. Finally, analyses for The Cancer Genome Atlas data set revealed that BCa patients with high expression levels of Siglec-7 have a poor survival rate. This work indicates that Siglec-7 may restrain NK-mediated antitumor immunity in BCa. PATIENT SUMMARY: We investigated the expression of proteins called Siglecs in natural killer (NK) cells from patients with bladder cancer. We showed that levels of the protein Siglec-7 in blood, urine, and tumors from patients with bladder cancer are associated with poor clinical outcomes. Thus, Siglec-7 may be involved in the regulation of antitumor immunity mediated by NK cells in bladder cancer.